Blood test could replace biopsy for rare cancer treated by Keytruda
Guardant Health, a biotechnology company, says its blood test could replace biopsy for rare cancer treated by Keytruda.
Two years ago, the Food and Drug Administration marked a big step forward in the way doctors think about cancer: It approved Merck’s Keytruda to treat tumors that appear anywhere in the body, but are marked
